Allergy

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

The investigators of this new data note that integration using a standardized process which is EMR-based may be the next thing to move for, to better address the overreporting of penicillin allergy.

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

This test provides a useful approach as it can be less intensive for time and resources, less costly, and it can be conducted outside of the specialist allergy setting.

The new research in this study indicates that both types of food challenges may be equally useful when conducted by trained staff who use strict objective stop criteria.

This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.

This recent research indicates the necessity for clinicians to be aware of the higher autoimmune disease susceptibility of those with previous rotavirus-associated hospitalization.

This new data on younger acute sinusitis patients may indicate the value of testing for specific bacteria at the time of presentation in order to lower the use of antibiotics for this condition.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

New data indicates associations between conditions for pregnant mothers and offspring, though a connection to offspring food allergy was not evident in this research.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

New data led to positive results for the simple-to-use PEN-FAST tool, allowing its use among allergists and even primary care physicians in cases in which access to allergists is limited.

This data indicates that public health officials may need to implement measures to both help prevent and detect domestic violence in order to reduce the associated effects.

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

Climate and vegetation changes in China may have led to increases in sensitivity to weed pollens and molds over the past 5 years, though the number one aeroallergen remains to be house dust mites.

Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.

These findings are relevant given that if labels are incorrectly identified, those with allergies may be at risk of severe reactions or receive suboptimal treatment.

New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

It was announced by ARS Pharmaceuticals, Inc., that a US Food and Drug Administration Drug Advisory Committee voted in favor of a new intranasal epinephrine treatment for severe allergic reactions.

IgE-mediated children with cow’s milk allergies switching from amino acid-based formula to a new formula showed strong tolerance and better acquisition of immune tolerance, suggesting other studies combining treatments may be useful.

In this interview segment, Fleischer further described some of the key points about the peanut immunotherapy patch, DBV712, and the product’s phase 3 VITESSE trial.

In his interview, Fleischer discussed the beginning of a new phase 3 trial for a peanut immunotherapy patch known as DBV712.